Company / Current Liabilities
NEKTAR THERAPEUTICS Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$53.5M
FY2025
5-year range
$51.3M / $85.2M
FY2021-FY2025
Trend
-12.8%
vs FY2024
Sector context
#137 of 213
Health Care
What the data says
At $54M, NEKTAR THERAPEUTICS's current liabilities ranks #77 of 213 in the Health Care sector. Current Liabilities has fluctuated over the past 10 years, ranging from $51M in FY2023 to $354M in FY2019.
Based on SEC 10-K filings.
$54M in FY2025 with a 5-year CAGR of -14.3%.
Increased from $51M to $54M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -7.8%
- 5-Year CAGR
- -14.3%
- 10-Year CAGR
- -
Sector benchmark
#77 of 213 in Health CareTop 36% of 213This company $53.5M Sector average $1.6B
▼
-96.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -14.3%, indicating a declining trend.
- In FY2025, current liabilities decreased 12.8% year-over-year.
- Ranks #137 out of 213 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $53.5M | -12.8% |
| FY2024 | $61.4M | +19.8% |
| FY2023 | $51.3M | -24.8% |
| FY2022 | $68.2M | -19.9% |
| FY2021 | $85.2M | -26.4% |
| FY2020 | $115.8M | -67.3% |
| FY2019 | $353.9M | +331.6% |
| FY2018 | $82.0M | +46.0% |
| FY2017 | $56.2M | -22.2% |
| FY2016 | $72.2M | +17.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026